Tuoxin Pharmaceutical Group Co (301089.SZ) Stock Price

Tuoxin Pharmaceutical Group Co Price

CLOSED
18.13
​
Market closed

Revenue has compounded at 0.1% per year over the past 12 years to 378.34 M CNY. Earnings per share have grown at 29.7% per year over the last 10 years. Tuoxin Pharmaceutical Group Co's net margin stands at -18.4%, down from 13.1% several years earlier. Tuoxin Pharmaceutical Group Co currently offers a dividend yield of about 1.38%. The dividend has grown at 58.1% per year over the past 2 years.

Tuoxin Pharmaceutical Group Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tuoxin Pharmaceutical Group Co business model & stock analysis

Tuoxin Pharmaceutical Group Co Ltd develops and sells chemical synthetic biological fermented nucleoside APIs and pharmaceutical intermediates. The company's main products include pyrimidine series, purine series, nucleotide series, nucleoside series, and other nucleoside (acid) products such as citicoline sodium, ribavirin, inosine, acyclovir, azvudine, cytosine, 5-fluorocytosine, cytidine, and uridine. These products serve the virus, anti-tumor, and nervous system drug markets. Tuoxin primarily sells its products domestically and internationally, targeting pharmaceutical companies that manufacture antiviral, anticancer, and neurological medications. The firm's revenue comes from the sale of these raw materials and intermediates to both domestic and overseas pharmaceutical manufacturers. The company focuses on nucleoside (acid) products for pharmaceutical applications, with key offerings like citicoline sodium and ribavirin used in antiviral treatments. Its product portfolio includes acyclovir for viral infections and azvudine for HIV treatment, alongside intermediates such as cytosine and uridine. Tuoxin's sales are directed toward pharmaceutical manufacturers in China and abroad, who incorporate these materials into their drug production processes. The firm's business model relies on supplying essential raw materials to the global pharmaceutical industry for the production of antiviral, anticancer, and neurological drugs. Tuoxin Pharmaceutical Group's revenue streams are derived from the production and sale of nucleoside-based APIs and intermediates. The company's primary customers are pharmaceutical manufacturers that require these materials for developing virus, anti-tumor, and nervous system drugs. The products are distributed across domestic and international markets, with the firm maintaining a focus on chemical synthetic biological fermented nucleoside products. The business model emphasizes direct sales of raw materials and intermediates to manufacturers rather than consumer-facing products.

Frequently asked questions about Tuoxin Pharmaceutical Group Co

Converted at the current exchange rate, the Tuoxin Pharmaceutical Group Co share trades at 2.47 EUR (18.13 CNY).

The revenue cannot currently be calculated for Tuoxin Pharmaceutical Group Co.

The profit cannot currently be calculated for Tuoxin Pharmaceutical Group Co.

The P/E ratio cannot be calculated for Tuoxin Pharmaceutical Group Co at the moment.

The P/S cannot be calculated for Tuoxin Pharmaceutical Group Co currently.

The Eulerpool Quality Score for Tuoxin Pharmaceutical Group Co is 2/10.

The ISIN of Tuoxin Pharmaceutical Group Co is CNE100004YC3. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Tuoxin Pharmaceutical Group Co is 301089.SZ. The ticker symbol is used to trade Tuoxin Pharmaceutical Group Co shares on the stock exchange.

Fair ValueTerminal
17.95 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
253,751.56 CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
CNY
Initial public offering
Oct 27, 2021
ISIN
CNE100004YC3
Cusip
Y972SH105
Market capitalization
2.29 B CNYMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
1.55
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-4.69 %
Dividend
Dividend yield
0.00 %
Payout Ratio
12.61 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
0 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
10.00 %
Last updated Nov 22, 2026, 3:41 AM

Tuoxin Pharmaceutical Group Co Peer Group

Tuoxin Pharmaceutical Group Co FIGI

301089:CH · BBG001CKTSY9301089:CS · BBG00W2L1NW3301089:C2 · BBG01BWNBKF5